Expert insights outline treatment protocols for PLLA-SCA™, highlighting safety and effectiveness in clinical use with lidocaine.
Increasing experience in the use of PLLA-SCA™ suggests that a brief overview of recent studies and a standardization of treatment protocols based on new clinical data should be beneficial. The aim of this article is to provide guidance on the use of PLLA-SCA™ based on data from the literature and the experience of five plastic surgeons and one aesthetic physician, with a focus on Italian patients. To this effect, the authors convened online to discuss various aspects related to PLLA-SCA™ treatment of both the face and non-facial body areas. For each topic, the authors developed recommendations, addressing patient selection, product preparation and injection protocols. Suggestions regarding the combination of PLLA-SCA™ with other aesthetic treatments and the prevention of adverse events were also included. The authors suggest using dilution volumes of 8 mL of sterile water for injection (SWFI) plus 1 mL lidocaine for the face and 17 mL SWFI plus 1 mL lidocaine for body areas and immediate use after product reconstitution. By adhering to the latest instructions about product reconstitution, the occurrence of complications is minimized. In the Authors’ experience, PLLA-SCA™ can be used safely and effectively for cosmetic enhancement of multiple body areas.
No takes yet. Share an insight, caveat, or question.
Innocenti et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: